R&D | December 07, 2025
Bayer advances fight against rare kidney disease with new experimental drug
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
Subscribe To Our Newsletter & Stay Updated
